 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- Jakafi (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
POOLED FECAL ALLOGENEIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE : RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE (Hall 5) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2275;
P3
GI-response correlates with increased OS, suggesting a favorable benefit-risk profile for MaaT013. A Phase 3 trial is currently ongoing to confirm these results in ruxolitinib-refractory patients (NCT04769895).
- MaaT033 / MaaT Pharma
A MULTICENTRE, RANDOMIZED, DOUBLE-BLINDED, PHASE 2B TRIAL EVALUATING MAAT033, AN ORAL, POOLED MICROBIOME ECOSYSTEM THERAPY IN ALLOHCT PATIENTS TO IMPROVE OVERALL SURVIVAL : PHOEBUS TRIAL (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_811;
P2b
The study has already been approved in France and Germany; expansion to other countries is planned for 2024. Study recruitment is ongoing since november 2023
- MaaT033 / MaaT Pharma
A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating the Efficacy and Safety of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy in Patients Undergoing Allogenic Hematop... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6408;
P2b
Exclusion criteria comprise non-myeloablative conditioning regimen, conventional myeloablative conditioning regimen, in-vitro T-cell depletion, alloHCT with cord blood cells, alloHCT from an unrelated donor with = 3/10 HLA-mismatches, use of alemtuzumab, vedolizumab or abatacept for GvHD prophylaxis, history of chronic digestive disease...Exploratory endpoints will describe the impact of MaaT013 on immune recovery, the nutritional status of the patients, and resource utilization...The study is approved in France and Germany; expansion to other countries is planned for 2024. Study start is expected in September 2023.
- Jakafi (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_4502;
P3
Interestingly, response of GI-aGvHD correlates with increased overall survival, suggesting a strong favorable benefit-risk profile for MaaT013. A Phase 3 trial is currently ongoing to confirm these results in ruxolitinib-refractory patients (NCT04769895).
- || MaaT013 / MaaT Pharma
P2 data, Journal: Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial. (Pubmed Central) - Sep 1, 2023
P2
Overall, MaaT013 was safe in this population of highly immunocompromised patients and was associated with responses in some patients with GI-aGvHD and deserves further investigation. MaaT Pharma.
- || MaaT013 / MaaT Pharma
Trial completion date, Trial primary completion date: ORION: Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (clinicaltrials.gov) - Aug 1, 2023
P=N/A, N=40, Recruiting, Sponsor: MaaT Pharma
MaaT Pharma. Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Jun 2024
- ||| MaaT013 / MaaT Pharma
Happy to share this important phase II study evaluating pooled allogeneic faecal microbiota MaaT013 for SR GI aGVHD https://t.co/SPISmr5sQ0 @Mohty_EBMT @MaaT_Pharma (Twitter) - Jul 26, 2023
- |||| MaaT013 / MaaT Pharma
🔔[COMMUNIQUE DE PRESSE] – MaaT Pharma est fier d’annoncer la publication de résultats cliniques dans @eClinicalMed @TheLancet mettant en évidence les bénéfices cliniques de #MaaT013 dans l’aGvH. 👉 https://t.co/rbRp997rsp @Mohty_EBMT @Florent_Malard @eBioMedicine (Twitter) - Jul 26, 2023
- |||||| MaaT013 / MaaT Pharma
Clinical: 🔔[Press Release]-MaaT Pharma is proud to announce the publication of results in @eClinicalMed, one of @TheLancet journals, highlighting the clinical benefits of MaaT013 in the treatment of aGvHD. @Mohty_EBMT @Florent_Malard @eBioMedicine 👉https://t.co/Ku9Aa1gzet (Twitter) - Jul 26, 2023
- ||||| MaaT033 / MaaT Pharma, MaaT013 / MaaT Pharma
Clinical data: 📅 #EBMT23 – Pr. @Florent_Malard will be sharing today promising clinical data for #MaaT013 in the Early Access Program in France and for our second drug candidate, #MaaT033, in Phase 1b study in AML at the 49th Annual Meeting of @TheEBMT. 👉 https://t.co/rw3N8le05t (1/3) (Twitter) - Apr 25, 2023
- ||| MaaT013 / MaaT Pharma
Clinical: to the #EBMT23 community MaaT013 for salvage aGvHD could be accessible in the US for clinical evaluation (Twitter) - Apr 23, 2023
- |||| MaaT033 / MaaT Pharma, MaaT013 / MaaT Pharma
🔔 #EBMT2023 : Prof. @Florent_Malard présentera des données prometteuses pour #MaaT013 et #MaaT033 à la 49ème rencontre annuelle de l’@EBMT. Ces données avaient déjà été partagées à l’édition 2022 de l’@ASH_hematology. 👉 https://t.co/hdpfb6TtBe (Twitter) - Apr 11, 2023
- Jakafi (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
POOLED FECAL ALLOGENIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: RESULTS FROM THE EARLY ACCESS PROGRAM IN FRANCE (AMPHITHEATRE BLEU) - Feb 11, 2023 - Abstract #EBMT2023EBMT_863;
P3
Interestingly, GI-aGVHD response correlates with increased OS, suggesting a strong favorable benefit-risk profile for MaaT013. A Phase 3 trial is ongoing in ruxolitinib-refractory patients (NCT04769895).
- ||||| MaaT013 / MaaT Pharma
Clinical: #ASH22 | @Mohty_EBMT discussed MaaT013 for the treatment of GI-aGvHD. At Day 28, overall response was 49% and 56% of patients achieved a GI overall response. Read more: https://t.co/657Q0dsssV #GvHD #gvhdsm #bmtsm (Twitter) - Jan 20, 2023
- ||||| Jakafi (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
Clinical: #ASH22 Abstract 112 @Mohty_EBMT presenting the results of the pooled allogeneic microbiotherapy MaaT013 Early Access Program in France. ✅MaaT013 is highly effective therapy for S- and SD-GI- aGVHD ✅Excellent responses in the ruxolitinib-refractory patients ✅Response = ↗️OS (Twitter) - Dec 10, 2022
- |||| MaaT013 / MaaT Pharma
MaaT013 pooled microbiota 🦠💩compassionate use for refractory GI #GVHD. 61% CR in rux failure, 92% response in steroid dependent GVHD. @Mohty_EBMT navigating the challenge of the hybrid meeting platform with grace. 🕺 #ASH22 (Twitter) - Dec 10, 2022
- |||| MaaT033 / MaaT Pharma, MaaT013 / MaaT Pharma
Clinical data: Join @E_plantamura, @HAffagard, Prof. @Mohty_EBMT and Prof @Florent_Malard for our #investor webcast on Monday, Dec. 12 at 6:00pm CET to discuss our latest clinical data for #MaaT013 and #MaaT033 presented over the weekend at #ASH22. Register here 👉 https://t.co/6SgCAroPhR (Twitter) - Dec 9, 2022
- Jakafi (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France (ENMCC - 252-254) - Nov 4, 2022 - Abstract #ASH2022ASH_1428;
P3
Interestingly, GI-response to aGvHD correlates with increased OS, suggesting a strong favorable benefit-risk profile for MaaT013. A Phase 3 trial is currently ongoing to confirm these results in ruxolitinib-refractory patients (NCT04769895).
- |||| MaaT013 / MaaT Pharma
Enrollment open, Trial completion date, Trial primary completion date: ARES: MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (clinicaltrials.gov) - Jun 24, 2022
P3, N=75, Recruiting, Sponsor: MaaT Pharma
A Phase 3 trial is currently ongoing to confirm these results in ruxolitinib-refractory patients (NCT04769895). Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: May 2023 --> Sep 2023
- ||| MaaT013 / MaaT Pharma
Enrollment open, Trial completion date, Trial primary completion date: ORION: Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (clinicaltrials.gov) - Jun 24, 2022
P=N/A, N=40, Recruiting, Sponsor: MaaT Pharma
Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: May 2023 --> Sep 2023 Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Mar 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
- | MaaT013 / MaaT Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open: PICASSO: Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (clinicaltrials.gov) - Mar 28, 2022
P2, N=60, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Mar 2024 | Trial primary completion date: Aug 2022 --> Aug 2023 Not yet recruiting --> Recruiting
- |||| MaaT013 / MaaT Pharma
Clinical: (ANNONCE CLINIQUE – PREMIER PATIENT DANS UNE ETUDE DE PHASE 3) - 🔔 Nous sommes fiers d’annoncer l’entrée en #Phase3 de #MaaT013 dans la maladie aiguë du greffon contre l’hôte (#aGvH). https://t.co/2ROJLdYBWF @E_plantamura @Mohty_EBMT @Florent_Malard @HAffagard (Twitter) - Mar 28, 2022
- ||||| MaaT013 / MaaT Pharma
Clinical: (CLINICAL ANNOUNCEMENT - LAUNCH OF PHASE 3) - 🔔 We are thrilled to announce that #MaaT013 is entering #Phase3 clinical trial in #aGvHD. See press release: https://t.co/2t1CP3JIex @E_plantamura @Mohty_EBMT @Florent_Malard @HAffagard (Twitter) - Mar 28, 2022
- ||||| MaaT013 / MaaT Pharma
Clinical, P2 data: #EBMT22 Abstract OS10-06 @Florent_Malard et al. HERACLES Phase 2 trial MaaT013, a fecal microbiotherapy for steroid-refractory aGVHD: ✅ is effective • HERACLES: D28 ORR 38% and CR 21% • EAP: D28 ORR 58% and CR 33% ✅ is safe in highly immunosuppressed patients cc @Mohty_EBMT (Twitter) - Mar 23, 2022
- MaaT013 / MaaT Pharma
POOLED ALLOGENIC FECAL MICROBIOTHERAPY MAAT013 FOR THE TREATMENT OF STEROID-REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: RESULTS FROM THE PHASE IIA HERACLES STUDY AND EXPANDED ACCESS PROGRAM (South Hall 2A+B / Virtual Hall 5) - Jan 30, 2022 - Abstract #EBMT2022EBMT_930;
P2
We report the treatment of 76 SR-GI-aGvHD patients using a pooled-donor-MET. The D28-GI-ORR was 38% (HERACLES) and 58% (EAP) and this clinical benefit significantly impacted M12-OS: 44% (HERACLES) and 62% (EAP) in R-patients.
- |||| MaaT013 / MaaT Pharma
#ASHKudos to @Florent_Malard facing technical difficulties and presenting the results of the Heracles study MaaT013 for SR #GVHD, 54% best GI GVHD response at D28, 1-y OS in responding pt 44% #ASH21 @Mohty_EBMT (Twitter) - Dec 11, 2021
- MaaT013 / MaaT Pharma
Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program (GWCC - B304-B305, Level 3) - Nov 5, 2021 - Abstract #ASH2021ASH_1574;
P2
The D28 GI-ORR was 38% and 60% in HERACLES and EAP respectively and this clinical benefit positively and significantly impacted OS (44% and 62% M12 in HERACLES and EAP R patients respectively). MaaT013 was shown to be safe and effective in these heavily immunocompromised patients, warranting further exploration of this approach.
- ||| MaaT013 / MaaT Pharma
New trial: ORION: Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (clinicaltrials.gov) - Aug 23, 2021
P=N/A, N=40, Not yet recruiting, Sponsor: MaaT Pharma
- | MaaT013 / MaaT Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
New P2 trial: PICASSO: Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (clinicaltrials.gov) - Aug 3, 2021
P2, N=60, Not yet recruiting, Sponsor: Assistance Publique - H
- ||||| MaaT013 / MaaT Pharma
Clinical: We are happy to announce positive topline #data from our Phase 2 #clinicaltrial, HERACLES with our lead #MicrobiomeEcosytemTherapy #MaaT013 in SR-GI-acute #GvHD patients. To read more, click https://t.co/mFGv2mfvXT @Mohty_EBMT (Twitter) - Mar 17, 2021
- |||||||| MaaT013 / MaaT Pharma
New P3 trial: ARES: MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (clinicaltrials.gov) - Feb 25, 2021
P3, N=75, Not yet recruiting, Sponsor: MaaT Pharma
- |||||| MaaT013 / MaaT Pharma
New trial: ATLAS: Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (clinicaltrials.gov) - Feb 24, 2021
P, N=0, Available, Sponsor: MaaT Pharma
- || MaaT013 / MaaT Pharma
Trial completion: HERACLES: Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer (clinicaltrials.gov) - Feb 23, 2021
P2, N=24, Completed, Sponsor: MaaT Pharma
MaaT013 was shown to be safe and effective in these heavily immunocompromised patients, warranting further exploration of this approach. Active, not recruiting --> Completed
- ||| MaaT013 / MaaT Pharma
#MaaT013: a next-gen fecal microbiota transfer product shows promise in #GvHD, with @Mohty_EBMT of @HopSaintAntoine Watch here: https://t.co/EsOpVWWJPm #ASH20 @ASH_hematology #HemOnc #BMTsm #CTSM #TrialUpdate (Twitter) - Feb 8, 2021
- Jakafi oral (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT PROGRAM (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1736;
We herein report for the first time the treatment of 29 patients with steroid-dependent or SR intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 59% with the off-the-shelf MaaT013 product, which was shown to be safe and effective in these heavily pre-treated and immunocompromised patients, warranting further exploration of the full ecosystem microbiota restoration approach.
- Jakafi oral (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT PROGRAM (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1735;
We herein report for the first time the treatment of 29 patients with steroid-dependent or SR intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 59% with the off-the-shelf MaaT013 product, which was shown to be safe and effective in these heavily pre-treated and immunocompromised patients, warranting further exploration of the full ecosystem microbiota restoration approach.
- Jakafi oral (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT PROGRAM (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1734;
We herein report for the first time the treatment of 29 patients with steroid-dependent or SR intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 59% with the off-the-shelf MaaT013 product, which was shown to be safe and effective in these heavily pre-treated and immunocompromised patients, warranting further exploration of the full ecosystem microbiota restoration approach.
- Jakafi oral (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT PROGRAM (On-Demand Library) - Feb 4, 2021 - Abstract #EBMT2021EBMT_1733;
We herein report for the first time the treatment of 29 patients with steroid-dependent or SR intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 59% with the off-the-shelf MaaT013 product, which was shown to be safe and effective in these heavily pre-treated and immunocompromised patients, warranting further exploration of the full ecosystem microbiota restoration approach.
- |||| MaaT013 / MaaT Pharma
[2/2] OS was 46% at 12 months after FMT with the next-gen product MaaT013 in steroid refractory intestinal acute GVHD. Here’s the link to read the abstract 👉 https://t.co/DVbxYhQXPK #ASH20 #gvhdsm @MaaT_Pharma @Mohty_EBMT @gvhd_hub (Twitter) - Dec 7, 2020
- Jakafi oral (ruxolitinib) / Novartis, Incyte, MaaT013 / MaaT Pharma
[VIRTUAL] Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program (Channel 23 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3149;
Conclusions We herein report for the first time the treatment of 29 patients with steroid-dependent or SR intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 59% with the off-the-shelf MaaT013 product, which was shown to be safe and effective in these heavily pre-treated and immunocompromised patients, warranting further exploration of the full ecosystem microbiota restoration approach.
- MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5184;
We report for the first time the treatment of 11 patients with steroid-dependent or steroid-refractory intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 82% with the off-the-shelf MaaT013 product, shown to be safe and effective in these immunocompromised patients with severe conditions, warranting further exploration of the full ecosystem microbiota restoration approach.
- MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5183;
We report for the first time the treatment of 11 patients with steroid-dependent or steroid-refractory intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 82% with the off-the-shelf MaaT013 product, shown to be safe and effective in these immunocompromised patients with severe conditions, warranting further exploration of the full ecosystem microbiota restoration approach.
- MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5182;
We report for the first time the treatment of 11 patients with steroid-dependent or steroid-refractory intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 82% with the off-the-shelf MaaT013 product, shown to be safe and effective in these immunocompromised patients with severe conditions, warranting further exploration of the full ecosystem microbiota restoration approach.
- | MaaT013 / MaaT Pharma
Enrollment closed, Trial completion date, Trial primary completion date: HERACLES: Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer (clinicaltrials.gov) - May 21, 2020
P2, N=32, Active, not recruiting, Sponsor: MaaT Pharma
The overall response rate was 82% with the off-the-shelf MaaT013 product, shown to be safe and effective in these immunocompromised patients with severe conditions, warranting further exploration of the full ecosystem microbiota restoration approach. Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jan 2020
- |||| MaaT013 / MaaT Pharma
GvHD focused SAB formation to support the design of our next step of development. Thank you, Dr Ernst Holler (chairman), Dr Madan Jagasia, Dr @RobJenqMD , Dr @Florent_Malard and Dr Zeiser for joining. #MaaT013 #Microbiome #GvHD @dorejoel @Mohty_EBMT https://t.co/rfstr4ekWv (Twitter) - May 15, 2020
- MaaT013 / MaaT Pharma
[VIRTUAL] SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_2075;
We report for the first time the treatment of 11 patients with steroid-dependent or steroid-refractory intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. The overall response rate was 82% with the off-the-shelf MaaT013 product, shown to be safe and effective in these immunocompromised patients with severe conditions, warranting further exploration of the full ecosystem microbiota restoration approach.
- |||| MaaT013 / MaaT Pharma
@E_plantamura and Dr. Ronald Carter will present GvHD data today during #ASH2019 ! Come visit us to talk about our lead Microbiota Biotherapeutics : #MaaT013. #ASH19 #Microbiome #GvHD @ASH_hematology @Florent_Malard @Mohty_EBMT (Twitter) - Dec 7, 2019
- |||| MaaT013 / MaaT Pharma
@E_plantamura and Dr. Ronald Carter will present GvHD data today during #ASH2019 ! Come visit us to talk about our lead Microbiota Biotherapeutics : #ASH19 #MaaT013. #ASH2019 #Microbiome #GvHD @ASH_hematology @Florent_Malard @Mohty_EBMT (Twitter) - Dec 7, 2019
- |||| MaaT013 / MaaT Pharma
Our CMO Dr. Ron Carter will present GvHD data tomorow during #ASH2019 ! Come visit us to talk about our lead Microbiota Biotherapeutics : #MaaT013. #ASH2019 #Microbiome #GvHD @ASH_hematology @Florent_Malard @Mohty_EBMT (Twitter) - Dec 6, 2019
- ||||| MaaT013 / MaaT Pharma
Clinical: Le #Microbiote des patients #AML recevant un traitement 3+7 peut-être ramené à son été antérieur grâce au Transfert de Microbiote Fecal. @Mohty_EBMT #MaaT013 #MaaT033 #SFGMTC19 (Twitter) - Nov 7, 2019